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Abstract
The use of plasma growth factors is opening a new field of clinical application in medicine, 
developing a new discipline called regenerative medicine. In many fields such as trauma-
tology, dental implantology or anesthesia, the use of this biotechnology is improving the 
quality of life of patients, through techniques that are not invasive but with extraordinary 
functional results. A discipline where this type of procedure opens an interesting field of 
application is undoubtedly neurology, especially those processes of ischemic or hypo-
anoxic origin such as cerebral palsy, where recent studies point to an improvement of 
cognitive abilities in patients, together with specific neurorehabilitation therapies.
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1. Introduction
The use of plasma rich in growth factors in various fields of medicine especially orthopedics, 
dentistry, and general surgery has experienced an extraordinary development given the enor-
mous capacity for regeneration, differentiation and chemotaxis that produce so-called growth 
factors, modulating angiogenesis, and cellular plasticity of injured tissues. Among them the best 
known are: insulin-like growth factor (IGF-1), transforming growth factor A or B (TGF-A B), 
vasculo-endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) [1, 2].
Through complex biochemical regulatory feedback-type mechanism that involves numer-
ous cytokines, the injured cell f has specific receptors for these proteins which have shown 
great power to intervene in apoptotic and antiapoptotic mechanisms that regulate both their 
own life cycle and as cell differentiation. Also recent studies have objectified the possibility 
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of improve levels of certain plasma growth factors depending on the platelet or mononuclear 
predominance of the product finally obtained [3, 4].
An emerging medical field of application is undoubtedly neurology, especially those pro-
cesses of anoxic or hypoxic ischemic origin, including cerebral palsy. The immunomodula-
tory and proangiogenic effect that plasma growth factors have on neurogenesis opens up a 
surprising range of treatment possibilities together with neurorehabilitation with the aim of 
improving functional capacity in these patient with the aim of improving functional capac-
ity in these patients, especially in the cognitive area: language, memory, ability to perform 
complex tasks, etc., using a technique that is minimally invasive, easy to reproduce and with 
a very low economic cost [4–6] (Figure 1).
Figure 1. Effects of growth factors in neural tissue.
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2. Plasma growth factor functions
PDGF (platelet-derived growth factor origin): promotes angiogenesis via macrophages by a 
mechanism of chemotaxis, having a significant mitogenic activity on neurons, microglia 
cells, making both proliferation and remyelination and facilitates the formation of type 1 
collagen [5, 7].
TGF-beta (transforming growth factor-beta): induces differentiation of neural stem cells.
FGF (fibroblast growth factor): enables the proliferation and differentiation of neural stem cells.
IGF-1 (insulin-like growth factor 1): it induces a potent mitotic effect on neural progenitor stem 
cellularity.
VEGF (vasculo-endothelial growth factor): enables chemotaxis and differentiation neural cells 
promoting blood vessel air permeability.
Ectodermal growth factor (EGF): great proapoptotical capacity, chemotaxis on neural and glial cells.
BDNF (brain-derived neurotrophic factor): produces proliferation, differentiation and neuronal 
chemotaxis on microglial and oligodendrocitarial cellularity and remyelination thereof.
HGF (hepatocyte growth factor): induces cell proliferation and differentiation, chemotaxis, 
angiogenesis and extracellular matrix synthesis (Table 1).
Content Feature
Chemokines, cytokines
Platelet factor 4
B-tromboglobina
RANTES*
Macrophage inflammatory protein 1-alpha
Interleukin 1 and 8
Regulation of inflammation, chemotaxis
Adhesive proteins
1 and 2 thrombosin
Fibrinogen
Fibronectin
Cell interactions and coagulation
Growth
Platelet-derived growth factor (PDGF)
Transforming growth factor b (TGF-B)
Epidermal or epithelial growth factor 
(EDGF)
Vasculo-endothelial growth factor (VEGF)
Insulin-like growth factor-1 (IGF-1)
Hepatocyte growth factor (HGF)
Brain-derived neurotrophic factor (BDNF)
Cell proliferation and differentiation, chemotaxis, angiogenesis, 
extracellular matrix synthesis
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3. Definition of plasma growth factors
Growth factors are obtained in an autologous way from the whole blood of the same 
patient with the aim of reducing the possibility of producing hypersensitivity effects or 
transmission of infectious diseases during their application. It is called leukocyte-rich 
plasma or (PRL) to the suspension of the mononuclear fraction or buffy coat in a quantity 
of patient’s serum with a count higher than 20,000/ mm3; while platelet-rich plasma (PRP) 
would be that platelet concentrate suspension in a small amount of patient serum whose 
count exceeds 1000,000/mm3 of platelets. The optimum pH to obtain both cellular fractions 
is estimated between 6.5 and 6.7 at a temperature of 22°C. Recent studies, such as the 
one led by the group of Dr. Alcaraz et al., have observed the predominance of PDGF and 
IGF-like plasma growth factors in platelet-rich suspensions, while other growth factors 
such as VEGF or TGF would predominate in those final concentrates rich in leukocyte-
mononuclear cells [4–6] (Table 2).
Peripheral blood PRP
PDGF-AB (10–50 pg/ml) 45 pg/ml 360 pg/ml
TGF-B1 (10–70 pg/ml) 35 pg/ml 320 pg/ml
VEGF (15–85 pg/ml) 55 pg/ml 560 pg/ml
IGF-1 (0.5–19.5 pg/ml) 13 pg/ml 175 pg/ml
Platelets (150,000–350,000/mm3) 265,000/mm3 1,250,000/mm3
Leucocytes (3200–9000/mm3) 5600/mm3 20,000/mm3
Granulocytes 60% (3330/mm3) 24% (480/mm3)
Mononuclears 35% (1960/mm3) 70% (14,000/mm3)
CD 34+ 0.5/mm3 175/mm3
Table 2. Levels of growth factors and cell count in peripheral blood and PRP.
Content Feature
Immunoglobulins G
Ig-A, Ig-E, Ig-M and Ig-G
Immunological
Clotting factors V and VIII Thrombin production
Von-Willebrand factor Platelet adhesion to subendothelial collagen
plasminogen activator inhibitor Inhibition of fibrinolysis
P-selectin Leukocyte-platelet interaction
*Rantes: regulated on activation normal T cell expressed and secreted.
Table 1. Summary of the proteins in the platelet alpha granules.
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4. Plasma growth factors (PRP) in cerebral palsy
PRP produces a release of cellular signaling molecules only or in combination that have been 
shown to produce both neuroprotective and anti apoptotic effect on the neuron and adult 
neural stem cells repairing neural tissue. Plasma growth factors constitute support that facili-
tates the survival and neuronal differentiation [2, 3, 7].
It has been shown that application of autologous plasma growth factors had a neuroprotec-
tive and antifibrotic effect, improving nerve regeneration probably induced by the activation 
of the PI3K/Akt anti apoptotic signaling pathway [2].
We do not yet have enough studies to evaluate effect of angiogenesis in the nerve repair. 
Administration of autologous PRP rich in VEGF and IGF-1 accelerates the regeneration of the 
neuromuscular junction owing to the increase of angiogenesis. Intramuscular injections of 
PRP would increase the angiogenesis and produces reperfusion after the induction of a severe 
skeletal muscle ischemia [2, 3, 7].
The main function of PRP has been showed in a rat brain sample, where application of plasma 
growth factors induced both the increase in the number and the growth of axons. The PRP 
has been used in a model of acute cerebral nerve injury in rabbits, as a culture medium to 
neurological stem cells reporting beneficial effects on axonal count, myelination and electro-
physiological functionality. PRP could increase both the thickness of the myelin and amount 
of axons, producing an increase in functional activity at the date of latency associated with 
improvement in the thickness of the myelin. PPR could contribute significantly to the two key 
events for a proper axonal regeneration: angiogenesis and the establishment of an optimal 
microenvironment for the differentiation, immunomodulation and cell division [1–3, 5, 6].
It has been objectified an anti-inflammatory activity of PRP, aiming that b-amyloid expresses 
cytokines inhibited when astrocytes are cultivated with autologous growth factors, that could be 
explained by suppression of NFkB in astrocytes with the activation of the Cyclooxygenase and 
the expression of tumor necrosis factor in the brain. Several studies have reported that plasma 
growth factors like IGF-1, PDGF and TGF-B, could inhibit the NFkB on the tenocytes, synovial 
cells, fibroblasts, chondrocytes and change the macrophages from phenotype M1 to M2 [2, 6, 7].
The growth factors would produce neurogenesis phenomena through 3 ways: first inhibit-
ing the inflammatory process that would difficult the anatomical and physiological neuronal 
recovery; secondly improving the migration and proliferation of stem neuronal cells at the 
site of the lesion and finally stimulating its differentiation toward mature neuronal mass rees-
tablishing the normal functional circuit of the same.
The lesion of a neuron actives macrophages and mononuclear cells like Monocytes that 
phagocyte the myelin residues, stimulating by autocrine way the nerve growth factor (NGF), 
that facilitates the recruitment of Schwann cells to the area of the lesion, their differentiation 
and proliferation join to the vasculo-endothelial growth factor producing remyelination and 
final reconnection of the affected axon.
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5. Discussion
The evolution of regenerative medicine in various clinical areas revolutionizes the field of tis-
sue repair, providing an instrument for treatment which is economical, easy to use, no side 
effects, and less invasive [1, 3]. However, scientific and social requirements make it necessary 
to design appropriate clinical trials to establish treatment protocols for each particular medical 
application [1, 2]. Today, medical areas with stronger scientific evidence to use plasma growth 
factors are dentistry (to repair the dental alveolar bed) and traumatology (arthropathy, tendi-
nopathy, ligament injuries, and meniscopathy), with proper design randomized clinical trials 
in phase I-II [1, 4]. But the empirical use in many diseases and medical specialties sometimes 
exceeds the capacity to produce sufficient scientific evidence power for use. An important 
fact to comment, as previously demonstrated by other authors is the great capacity of these 
proteins to spread through the tissues and the short half-life objectified once achieved thera-
peutic plasma levels that do not usually exceed 48–72 h [8, 9], which shows that the actuation 
mechanism is complex, it is believed that activating pathways or biochemical cascades through 
numerous chemokines or cytokines that involve in the inflammatory processes both specific 
tissue, such as migration, proliferation and differentiation of precursors cell maturation in dif-
ferent states and angiogenesis phenomena would produce increased tissue oxygenation with 
the consequent increase in cell survival and protection thereof. Some more promising medical 
fields for the use of this biotechnology are neurology, neuroendocrinology and neuroreha-
bilitation. A few months ago was published the first clinical case of cognitive improvement 
supported by cerebral PET in a 5 years old child with severe cerebral palsy who was applied 
by intravenous infusion a plasma concentrate growth factors-enriched with buffy-coat mono-
nuclear fraction. Several authors hypothesized neuroregenerative phenomena, antiapoptotic, 
immunomodulatory and neurotrophic effects that would produce these autologous plasma 
growth factors on neuronal tissue, making this a feasible therapy from a medical point of view, 
to be applied in neurological diseases with neurodegenerative profile or hypoxic-anoxic, such 
as Alzheimer’s disease, brain-stroke, spinal cord injury, and cerebral palsy [5, 6]. Spontaneous 
remission of the signs and symptoms of cerebral palsy is rare due to the large number of 
neuronal glial mass and degenerate secondary to the effects of hypoxia in the evolution of the 
disease [9]. Effects of neurostimulation, neurodegeneration and neuroprotection have been 
observed in these patients treated with synthetic growth hormone (HGF), which causes func-
tional improvement, especially in the cognitive domain (e.g., memory, language, ability to per-
form complex tasks, and acquisition of new skills). In these patients, the neuronal degenerative 
effect has been accompanied by a qualitative and quantitative marked decrease in plasma 
growth factors such as HGF-IGF-1-VEGD, PDGF, and TGF-B [7–9], regulated by the hypo-
thalamic axis pituitary, which produce a neuroprotective effect, due to neurotropic and che-
motaxis phenomena, cell differentiation, and neuroplasticity in neuronal tissue. Furthermore, 
these substances have the ability to stimulate the so-called gray areas corresponding to those 
neural tissues found in hibernation as a result of lesional hypoxic or anoxic effect. However, 
treatment with synthetic growth hormone is costly, not only from the economic standpoint but 
also from the clinical point of view.
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